 Insmed Incorporated Nasdaq:INSM, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that final results from the Phase 2 WILLOW study of brensocatib formerly INS1007 in patients with non-cystic fibrosis bronchiectasis NCFBE were presented during a virtual American Thoracic Society ATS session titled Breaking News: Clinical Trial Results in Pulmonary Medicine. Brensocatib is a novel, oral, reversible inhibitor of dipeptidyl peptidase 1 DPP1 being developed by Insmed for the treatment of bronchiectasis and other inflammatory diseases. 